<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 16, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02499770</url>
  </required_header>
  <id_info>
    <org_study_id>G1T28-02</org_study_id>
    <nct_id>NCT02499770</nct_id>
  </id_info>
  <brief_title>G1T28 (CDK 4/6 Inhibitor) in Combination With Etoposide and Carboplatin in Extensive Stage Small Cell Lung Cancer (SCLC)</brief_title>
  <official_title>Phase 1b/2a Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>G1 Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>G1 Therapeutics, Inc.</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to investigate the potential clinical benefit of G1T28 in protecting the
      bone marrow and preserving the immune system when administered prior to carboplatin and
      etoposide in first line treatment for patients with newly diagnosed extensive-stage SCLC.

      The study consists of 2 parts: a limited open-label, dose-finding portion (Part 1), and a
      randomized double-blind portion (Part 2). Both parts include 3 study phases: Screening
      Phase, Treatment Phase, and Survival Follow-up Phase. The Treatment Phase begins on the day
      of first dose with study treatment and completes at the Post-Treatment Visit. Approximately,
      80 patients will be enrolled in the study.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2015</start_date>
  <completion_date type="Anticipated">August 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Dose Limiting Toxicity</measure>
    <time_frame>Days 1-21 of Cycle 1</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment related adverse events (AE)</measure>
    <time_frame>Up to 24 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile for G1T28, Carboplatin and Etoposide</measure>
    <time_frame>Days 1 and 3 in Cycle 1</time_frame>
    <safety_issue>No</safety_issue>
    <description>Blood samples for the determination of G1T28, Carboplatin and Etoposide pharmacokinetics (PK) and its active metabolite(s) will be collected from all patients in Part 1. Blood samples will be collected prior to and after the administration of G1T28, Carboplatin and Etoposide on days 1 and 3 cycles 1 only.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 Months</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hematologic parameters</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The following will be assessed: hemoglobin, hematocrit, white blood cells with differential and platelet counts</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response based on RECIST, Version 1.1</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for RBC and platelet transfusions</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Need for treatment with hematopoietic growth factors</measure>
    <time_frame>Day 22</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chemotherapy dose reductions and dose interruptions overall</measure>
    <time_frame>Up to 20 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>G1T28 + carboplatin/ etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients in part 1 will receive G1T28 prior to standard chemotherapy- carboplatin and etoposide. Patients will have PK assessments completed on days 1 and 3 in cycle 1 only. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>G1T28/Placebo + carboplatin/ etoposide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients enrolled in part 2 will be randomized to receive either G1T28 or placebo administered prior to standard chemotherapy- carboplatin and etoposide. All patents will be monitored for safety and tumor response based on RECIST version 1.1. Safety surveillance reporting of AEs and concomitant medications commences at the time that informed consent is obtained and continues through the Post Treatment Visit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>G1T28 + carboplatin/ etoposide</intervention_name>
    <description>G1T28, carboplatin and etoposide.</description>
    <arm_group_label>G1T28 + carboplatin/ etoposide</arm_group_label>
    <arm_group_label>G1T28/Placebo + carboplatin/ etoposide</arm_group_label>
    <other_name>G1T28 (CDK 4/6 Inhibitor), carboplatin and etoposide.</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo + carboplatin/ etoposide</intervention_name>
    <description>Placebo, carboplatin and etoposide.</description>
    <arm_group_label>G1T28/Placebo + carboplatin/ etoposide</arm_group_label>
    <other_name>Placebo, carboplatin and etoposide</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects aged â‰¥18 years

          -  Histologically or cytologically confirmed confirmed diagnosis of SCLC, including the
             presence of neuroendocrine features by immunohistochemistry

          -  At least 1 target lesion that is unirradiated and measurable by RECIST, Version 1.1

          -  Eastern Cooperative Oncology Group (ECOG) performance status of 0 - 2

          -  Adequate organ function

        Exclusion Criteria:

          -  Prior chemotherapy for extensive-stage SCLC

          -  Presence of symptomatic brain metastases requiring immediate treatment with radiation
             therapy or steroids.

          -  Uncontrolled ischemic heart disease or uncontrolled symptomatic congestive heart
             failure

          -  Known history of stroke or cerebrovascular accident within 6 months prior to
             enrollment

          -  Other uncontrolled serious chronic disease or conditions that in the investigator's
             opinion could affect compliance or follow-up in the protocol

          -  Concurrent radiotherapy to any site or radiotherapy within 4 weeks prior to
             enrollment or previous radiotherapy to the target lesion sites (the sites that are to
             be followed for determination of a response)

          -  Receipt of any investigational medication within 4 weeks prior to enrollment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Contact</last_name>
    <role>Study Director</role>
    <affiliation>G1 Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>G1Therapeutics Clinical Contact</last_name>
    <email>clinicalinfo@g1therapeutics.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Genesis Cancer Center</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Laura Sellers, RN</last_name>
      <email>lsellers@genesiscancercenter.com</email>
    </contact>
    <investigator>
      <last_name>R. Timothy Webb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Hospital - Univ. of Colorado Health</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80909</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rentia Patrick</last_name>
      <email>renita.patrick@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Robert Hoyer, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Colorado Health, Oncology Clinical Research Northern Region</name>
      <address>
        <city>Ft. Collins</city>
        <state>Colorado</state>
        <zip>80528</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marlon Bazan</last_name>
      <email>marlon.bazan@uchealth.org</email>
    </contact>
    <investigator>
      <last_name>Steven Schuster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North</name>
      <address>
        <city>Tavares</city>
        <state>Florida</state>
        <zip>32778</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christine Biermeier</last_name>
      <phone>727-216-1143</phone>
    </contact>
    <investigator>
      <last_name>Maen Hussein, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - East</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Todd Gersten, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University Cancer and Blood Center, LLC</name>
      <address>
        <city>Athens</city>
        <state>Georgia</state>
        <zip>30607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jamie Hodgson</last_name>
      <phone>706-353-2990</phone>
      <phone_ext>279</phone_ext>
      <email>jhodgson@universitycancer.com</email>
    </contact>
    <investigator>
      <last_name>Petros Nikolanikos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Lowrie</last_name>
      <phone>404-778-1842</phone>
    </contact>
    <investigator>
      <last_name>Taofeek Owonikoko, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Harbin Clinic</name>
      <address>
        <city>Rome</city>
        <state>Georgia</state>
        <zip>30165</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Terri Brannon</last_name>
      <phone>706-528-9094</phone>
    </contact>
    <investigator>
      <last_name>Dilawar Khan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rush Univ. Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>John Barcenas</last_name>
      <phone>312-563-4593</phone>
    </contact>
    <investigator>
      <last_name>Marta Batus, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Univ. of Kentucky - Markey Cancer Center</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40536</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Susanne Arnold, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norton Cancer Institute</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Julie Brown</last_name>
    </contact>
    <investigator>
      <last_name>John Hamm, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Center For Cancer and Blood Disorders</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natalie Bongiorno, RN</last_name>
      <phone>301-571-2016</phone>
      <email>NBongiorno@CCBDMD.COM</email>
    </contact>
    <investigator>
      <last_name>Ralph Boccia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Andrew Kellum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Crystallee, Newton</last_name>
      <phone>603-650-4428</phone>
    </contact>
    <investigator>
      <last_name>Konstantin Dragnev, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Roswell Park</name>
      <address>
        <city>Buffalo</city>
        <state>New York</state>
        <zip>14263</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Hongbin Chen, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>North Shore Hematology Oncology Associates PC</name>
      <address>
        <city>East Setauket</city>
        <state>New York</state>
        <zip>11733</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>David Chu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mission Hospital, Inc.</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Christopher Chay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UNC - Lineberger Comprehensive Cancer Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27514</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jared Weiss, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cone Health Cancer Center</name>
      <address>
        <city>Greesnboro</city>
        <state>North Carolina</state>
        <zip>27403</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Mohamed Mohamed, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oklahoma University - Peggy and Charles Stephenson Cancer Center</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73117</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ingrid Block</last_name>
      <phone>405-271-8001</phone>
      <phone_ext>48160</phone_ext>
      <email>Ingrid-Block@ouhsc.edu</email>
    </contact>
    <investigator>
      <last_name>Raid Aljumaily, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AnMed Health</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rhonda Ballew</last_name>
      <phone>864-512-4651</phone>
    </contact>
    <investigator>
      <last_name>John Doster, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gibbs Cancer Center</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lisa Kirby</last_name>
      <email>lkirby@gibbscc.org</email>
    </contact>
    <investigator>
      <last_name>Caio Rocha-Lima, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Wellmont Cancer Institute</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Asheesh Shipstone, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hanna Cancer Associates - Univ of Tennessee</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shana Overby</last_name>
      <phone>865-305-9773</phone>
      <phone_ext>4</phone_ext>
      <email>soverbey@mc.utmck.edu</email>
    </contact>
    <investigator>
      <last_name>Wahid Hanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Meharry Medical College</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37208</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kim Thomas, RN</last_name>
      <phone>615-341-4228</phone>
    </contact>
    <investigator>
      <last_name>Phillip Lammers, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Texas Oncology</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Brandi Jackson</last_name>
      <phone>903-579-9800</phone>
      <email>Brandi.Jackson@usoncology.com</email>
    </contact>
    <investigator>
      <last_name>Donald Richards, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Bon Secours St. Francis Medical Center, Inc.</name>
      <address>
        <city>Midlothian</city>
        <state>Virginia</state>
        <zip>23114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lisa Driver</last_name>
      <phone>804-893-8663</phone>
    </contact>
    <investigator>
      <last_name>William Irvin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C.</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Judy Welch, RN</last_name>
      <phone>360-449-6522</phone>
    </contact>
    <investigator>
      <last_name>David Smith, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <lastchanged_date>February 1, 2016</lastchanged_date>
  <firstreceived_date>July 8, 2015</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Small Cell Lung Cancer</keyword>
  <keyword>CDK 4/6 Inhibitor</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Small Cell Lung Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Etoposide phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
